Open AccessSuccessful outcome of ganciclovir‐resistant cytomegalovirus infection in organ transplant recipients after conversion to mTOR inhibitors
Author(s) -
Sabé N.,
GonzálezCostello J.,
Rama I.,
Niubó J.,
Bodro M.,
Roca J.,
Cruzado J M.,
Manito N.,
Carratalà J.
Publication year - 2012
Publication title -
transplant international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.998
H-Index - 82
eISSN - 1432-2277
pISSN - 0934-0874
DOI - 10.1111/j.1432-2277.2012.01489.x
Subject(s) - medicine , ganciclovir , cytomegalovirus , immunosuppression , calcineurin , discovery and development of mtor inhibitors , organ transplantation , regimen , transplantation , everolimus , pi3k/akt/mtor pathway , cytomegalovirus infection , alemtuzumab , salvage therapy , immunology , sirolimus , human cytomegalovirus , herpesviridae , virus , chemotherapy , viral disease , signal transduction , biochemistry , chemistry
Summary Ganciclovir‐resistant (GanR) cytomegalovirus (CMV) infection after organ transplantation is emerging as a significant therapeutic challenge. We report two cases of GanR CMV infection successfully managed by switching immunosuppression from calcineurin inhibitors to an mTOR inhibitor‐based regimen. This salvage therapy should be considered when other options are not available.